Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank

Cancer immunotherapy has made remarkable advances with over 50 separate Food and Drug Administration (FDA) approvals as first- or second-line indications since 2015. These include immune checkpoint blocking antibodies, chimeric antigen receptor-transduced T cells, and bispecific T-cell–engaging anti...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Chuntova, Pavlina, Chow, Frances, Watchmaker, Payal B, Galvez, Mildred, Heimberger, Amy B, Newell, Evan W, Diaz, Aaron, DePinho, Ronald A, Li, Ming O, Wherry, E John, Mitchell, Duane, Terabe, Masaki, Wainwright, Derek A, Berzofsky, Jay A, Herold-Mende, Christel, Heath, James R, Lim, Michael, Margolin, Kim A, Chiocca, E Antonio, Kasahara, Noriyuki, Ellingson, Benjamin M, Brown, Christine E, Chen, Yvonne, Fecci, Peter E, Reardon, David A, Dunn, Gavin P, Liau, Linda M, Costello, Joseph F, Wick, Wolfgang, Cloughesy, Timothy, Timmer, William C, Wen, Patrick Y, Prins, Robert M, Platten, Michael, Okada, Hideho
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2020
Konular:
Meeting Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7992879/
https://ncbi.nlm.nih.gov/pubmed/33367885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa277
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller